A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Omar Beirat
Tudor Pop
Jenna Brashear
Tudor Pop
| Share Statistics | XENE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,825.9 | $288.9 | 69% |
|
| Shares Out (Mil) | 99.6 | 54.0 | 62% |
|
| Institutional Ownership | 99.9% | 93.1% | 96% |
|
| Float (Mil) | 91.0 | 41.4 | 59% |
|
| Beta | 0.63 | 0.94 | 37% |
|
| Avg Daily Volume (000s) | 675 | 480 | 65% |
|
| Price Change (52-week) |
53.1% | 59.9% | 82% |
|
| Growth | XENE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.3%) | 14.1% | 2% |
|
| Net Income (5yr) | (64.4%) | (10.1%) | 4% |
|
| EPS (5yr) | (40.4%) | 15.9% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 4.9% | (15.6%) | 67% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 14 | 16 | |
| Current EPS | ($1.159) | ($4.633) | ($4.866) | |
| Month Ago EPS | ($1.194) | ($4.810) | ($5.028) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 3 | 0 | 1 | |
| Three Months Ago EPS | ($1.194) | ($4.810) | ($5.009) | |
| Year/Year Chg | 4.2% | 6.1% | (8.5%) | |
| Financials | XENE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($409) | ($43) | 3% |
|
| EPS (TTM) | ($4.726) | ($1.500) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($338) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $2 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | $4,897 | $190 | 62% |
|
| Valuation | XENE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.69 | 2.84 | 77% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | XENE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (41.5%) | (47.7%) | 13% |
|
| ROE | (43.6%) | (55.0%) | 17% |
|
| Liabilities to Assets | 4.1% | 29.6% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Xenon Pharmaceuticals Inc. did not pass any screens on 9/2/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
